MADISON, Wis., June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities. Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid – to help ensure they have the staffing needed to achieve patient treatment goals.

As the field of radiation medicine has evolved since the X-ray was discovered 125+ years ago, so too has the TrueNorth team which now has an equivalent number of combined clinical years of experience. They will leverage this vast knowledge base to provide physics, dosimetry and commissioning support for the Accuray TomoTherapy^®, Radixact^® and CyberKnife^® Systems. TrueNorth offers specialized services that help augment a hospital's team and are tailored to their specific requirements. From providing additional staff while the site recruits new personnel or when only part-time assistance is desired, to sharing expertise that facilitates adoption of new technology and techniques, the company is equipped to meet these needs.

"We are excited about the opportunity to partner with Accuray and assist their customers. We have extensive experience working with Accuray's Radixact, TomoTherapy and CyberKnife platforms and are impressed with the unique features and associated benefits they provide," said Matt Daniels, Ph.D., DABR, one of the TrueNorth Managing Partners. "Nevertheless, we are an independent company with expertise across multiple industry platforms. Our organization is dedicated to providing unbiased feedback and support that improves the practice of radiation therapy medicine and enhances a team's ability to deliver care."

The addition of the TrueNorth offerings signifies a commitment from Accuray to provide an expanded range of solutions to help empower medical professionals from day one and throughout their tenure using the company's technology. The assistance they require will vary based on their clinical and economic goals, experience, and equipment age. Accuray offers a combination of standard and customizable services to align with differing preferences and circumstances, aimed at helping clinicians to deliver the best possible outcomes for patients.

"Accuray is committed to innovation in every aspect of our business, whether it be the radiotherapy technology we develop or the support we provide to customers to help them achieve their patient-focused treatment objectives," said Suzanne Winter, president and CEO of Accuray. "In today's dynamic and evolving healthcare environment, labor shortages and operational challenges may hinder hospitals from maintaining the staffing levels needed to meet their clinical demands and standards. We partnered with TrueNorth Medical Physics to provide care teams with another option for obtaining the resources they require to advance the treatment of cancer for more patients within their facilities."

About Accuray

Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the offerings provided by TrueNorth and the partnership with TrueNorth. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products and offerings; the company's ability to develop new products and offerings or improve existing products and offerings to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2024, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact
Beth Kaplan
Public Relations Director, Accuray
Phone +1 (408) 789-4426
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.